Severe Septicemic Melioidosis in a Patient With Lung Adenocarcinoma Following Cytotoxic Chemotherapy

Kuo-Hwa Chiang\textsuperscript{a,c}, Kuo-Chen Cheng\textsuperscript{a}, Hsi-Hsing Yang\textsuperscript{b}

Abstract

Melioidosis is an endemic disease in Southeast Asia and northern Australia, caused by \textit{Burkholderia pseudomallei}. Severe melioidosis pneumonia is typically life-threatening condition. It is relatively uncommon in patients with lung cancer. We report a case of melioidosis pneumonia with blood culture proved \textit{Burkholderia pseudomallei} in a patient with advanced stage lung adenocarcinoma following treatment with a gemcitabine containing regimen. To our knowledge, this is the first report on septicemic melioidosis pneumonia in lung adenocarcinoma patients following administration of cytotoxic chemotherapy.

Keywords: \textit{Burkholderia pseudomallei}; Septicemic melioidosis; Pneumonia; Lung adenocarcinoma; Cytotoxic chemotherapy

Introduction

Melioidosis is a disease of public health importance in Southeast Asia and northern Australia, which has the potential for epidemic spread to areas where it is not endemic [1, 2]. Pneumonia is the most common presenting feature of melioidosis, the disease caused by infection with \textit{Burkholderia pseudomallei} [1, 2]. Melioidosis pneumonia can be the primary presenting feature, can develop secondary to initial illness at a distant site, and can develop in patients with bacteremia without an initial evident focus [3]. Clinical progression of acute melioidosis pneumonia is often rapid, and septic shock and death are common outcomes, while severe septicemic melioidosis pneumonia is typically life-threatening [4]. Conditions predisposing to immunosuppression such as DM, liver cirrhosis, etc., can associate with septicemic melioidosis [4, 5]. Severe septicemic melioidosis following chemotherapy with gemcitabine containing regimen in advanced lung adenocarcinoma patient is extremely rare and has never been reported. We present a case of lung adenocarcinoma who received one course of chemotherapy with gemcitabine and cisplatin, and developed life-threatening pneumonia with blood culture proved \textit{Burkholderia pseudomallei}, while no neutropenia was noted at presentation. The patient was successfully treated with antibiotics treatment.

Case Report

We present a 70-year-old male, who was diagnosed as adenocarcinoma of lung right upper lobe with lung to lung metastasis 2 months prior to this admission, ever received chemotherapy with gemcitabine and cisplatin for one course and was discharged from our center with a stable disease condition, admitted to our ER due to fever, productive cough and progressive shortness of breath for days. The patient denied travelling history, nor contact history of influenza, etc. A complete blood count showed WBC of 11.7 × 10\textsuperscript{3}/μ, platelet of 655 × 10\textsuperscript{3}/μ, C-reactive protein showed 202 mg/L, the patient developed progressive worsening dyspnea shortly after admission, while an arterial blood gas analysis revealed severe hypoxemia with respiratory acidosis, he then received endotracheal intubation with mechanical ventilation, and transferred to ICU for further intensive care. A series of CXR (Fig. 2) showed progressive change from right upper lung nodular density (Fig. 2A) to right upper lobe consolidation and right lower lobe infiltrate (Fig. 2B) and then rapidly deteriorated to bilateral diffuse infiltrate with ARDS pattern (Fig. 2C). Unexpectedly, the blood culture indicated the presence of a strain of \textit{Burkholde-
Chiang et al. presented a case of a patient with a pneumonia caused by *Pseudomonas pseudomallei* that was susceptible to ceftazidime, imipenem, and minocycline. The patient received intravenous ceftazidime 2 g every 8 h for 2 weeks, with successful extubation on the eighth ICU day and transfer to the general ward the next day. Follow-up antibiotics treatment with ceftazidime 2 g q8h and minocycline 100 mg q12h for additional 3 weeks improved his condition. Follow-up blood culture showed no growth, and CXR revealed substantial improvement of the consolidation. He was discharged with stable condition and continued oral antibiotic treatment with doxycycline 100 mg twice a day, trimethoprim/sulfamethoxazole 80 mg/400 mg two tablets twice a day along with gefitinib 250 mg qd for his lung adenocarcinoma. The patient condition improved, and he completed the antibiotics treatment 20 weeks after discharge, with a smooth and stable disease condition.

**Discussion**

Lung infections can be severe consequences of chemotherapy-induced immune defects. Most of the cases are related to neutropenic condition. During the past decades, the attention in management of infections in cancer patients has focused on fever and neutropenia [6-8]. However, latest guidelines by the National Comprehensive Cancer Network recommend that immunocompromised non-neutropenic cancer patients should receive equal attention as those with neutropenia [9]. Cytotoxic drugs used for the treatment of lung cancer can affect chemotactic and phagocytic function, without reflecting on the...
total cell count. The functional capabilities of phagocytes such as neutrophils, eosinophils and mononuclear cells may be intrinsically defective even before the initiation of chemotherapy [6].

Severe septicemic melioidosis pneumonia with respiratory failure following administration of cytotoxic chemotherapy in lung adenocarcinoma patient is very rare; to our knowledge, this is the first case in English literature. Patients with septicemic melioidosis pneumonia can present severely unwell with fever and prostration, sometimes with few clinical features to suggest a focus of infection but with chest radiography revealing abnormalities consistent with bacteremic pneumonia, typically multiple nodular opacities or multiple patches of alveolar infiltration [3-5]. These cases often progress rapidly with coalescence of lesions, development of new lesions, and cavitation. Clinical progression of acute melioidosis pneumonia is often rapid, and septic shock and death are common outcomes [3-5]. Acute pneumonia with upper lobe consolidation in endemic regions warrants consideration of melioidosis.

Previous study demonstrated that acute septicemic melioidosis has an upper lobe predominancy in endemic regions, and may be initially misdiagnosed as having tuberculosis [10, 11]. The initial clinical presentations of pulmonary melioidosis can mimic tuberculosis, which exhibits fever, dyspnea, a loss of body weight, and fatigue [10]. It might be difficult to distinguish one from the other, unless microbiological information is confirmed [10, 11]. Previous study demonstrated that multi-systemic involvement, particularly multiple splenic abscesses, provides an important clue for melioidosis [12]. However, if the lesion coexists with lung tumor, as in our case, it represents a diagnostic and therapeutic challenge in the course of chemotherapy following diagnosis of lung cancer. In image study of a patient with lung adenocarcinoma under stable disease after chemotherapy, it might be mistakenly diagnosed as progressive disease with multiple spleen metastasis, or hilar lymph node metastasis especially when the melioidosis pneumonia developed initially. It is possible that the *Burkholderia pseudomallei* infection in our patient was community-acquired, and it is likely that the environment may play a role in *Burkholderia pseudomallei* infection in cancer patients, even those receiving less toxic chemotherapy. In some endemic area, melioidosis pneumonia should be considered in differential diagnosis of severe pneumonia after cytotoxic chemotherapy. This is a very important lesson in the care and management of patients on chemotherapy. The subtle and complicated nature of the course of this patient merits our emphasis on unusual presentation of severe pneumonia in newly diagnosed lung cancer patient. Physicians should be cautious to differentiate progressive disease or superimposed infection with an unusual presentation of severe community-acquired pneumonia in chemotherapy-treated patients.

### Declaration of Interest

We declare no conflict of interest. This article did not receive any funding from any institution.

### References